Published in J Virol on September 03, 2008
Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem (2008) 1.20
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol (2011) 1.04
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob Agents Chemother (2009) 1.03
Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem (2012) 0.97
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. Eur Biophys J (2011) 0.93
Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One (2012) 0.93
Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol (2011) 0.93
The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J Biol Chem (2012) 0.87
Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652. J Biol Chem (2012) 0.87
Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41. J Comput Chem (2013) 0.85
Crystal structures of beta- and gammaretrovirus fusion proteins reveal a role for electrostatic stapling in viral entry. J Virol (2013) 0.82
Computer-Aided Approaches for Targeting HIVgp41. Biology (Basel) (2012) 0.82
Immunization with hybrid proteins containing the membrane proximal external region of HIV-1. AIDS Res Hum Retroviruses (2014) 0.81
Pharmacophore-based similarity scoring for DOCK. J Phys Chem B (2014) 0.81
Charge-surrounded pockets and electrostatic interactions with small ions modulate the activity of retroviral fusion proteins. PLoS Pathog (2011) 0.81
Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK. Retrovirology (2014) 0.80
Structural basis of potent and broad HIV-1 fusion inhibitor CP32M. J Biol Chem (2012) 0.79
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket. J Virol (2015) 0.79
Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41. Biochemistry (2013) 0.78
DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes. Antimicrob Agents Chemother (2013) 0.77
Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket. J Virol (2015) 0.76
DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity. Nucleic Acid Ther (2015) 0.75
Raman spectroscopic signatures of echovirus 1 uncoating. J Virol (2014) 0.75
Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates. Front Immunol (2017) 0.75
Creating an artificial tail-anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors. J Virol (2016) 0.75
Enfuvirtide (T20)-based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implication for Viral Entry and Inhibition. J Virol (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry (1967) 21.79
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
HIV entry and its inhibition. Cell (1998) 9.42
Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem (2001) 8.96
Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry (1974) 8.54
A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol (1995) 7.30
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
HIV-1 inhibition by a peptide. Nature (1993) 5.01
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A (1998) 4.34
The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol (2003) 4.21
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses (1993) 3.80
Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J (1998) 3.77
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol (1991) 3.71
Protein design of an HIV-1 entry inhibitor. Science (2001) 3.38
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A (1998) 2.46
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol (1993) 2.21
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12
A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn (1997) 2.04
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem (2005) 1.99
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
HIV entry inhibitors. Lancet (2007) 1.73
Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1998) 1.69
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des (2007) 1.66
HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem (2007) 1.58
Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain. J Virol (1990) 1.56
AIDS virus envelope spike structure. Curr Opin Struct Biol (2007) 1.54
Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl (2002) 1.42
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides (2003) 1.41
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol (2001) 1.38
A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods (1999) 1.37
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry (2000) 1.36
Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A (2005) 1.36
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem (2007) 1.34
HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev (2004) 1.27
Surface salt bridges stabilize the GCN4 leucine zipper. Protein Sci (1998) 1.23
Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med (1991) 1.23
Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol (1999) 1.22
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol (2008) 1.20
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. Biochemistry (2002) 1.15
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J (2007) 1.14
Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology (2004) 1.11
Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (2000) 1.10
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J Biol Chem (2006) 1.02
Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity. J Virol (1998) 1.00
Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. J Mol Biol (2006) 1.00
An intrahelical salt bridge within the trigger site stabilizes the GCN4 leucine zipper. J Biol Chem (2000) 0.97
Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core. Biochemistry (2000) 0.96
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest (2005) 0.96
Interactions between HIV-1 gp41 core and detergents and their implications for membrane fusion. J Biol Chem (2000) 0.93
Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine (2003) 0.93
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine (2008) 0.91
Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1. Expert Opin Investig Drugs (2006) 0.90
How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. J Mol Biol (2003) 0.84
A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex. J Biol Chem (2007) 0.84
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
RePS: a sequence assembler that masks exact repeats identified from the shotgun data. Genome Res (2002) 4.35
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature (2008) 3.06
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest (2008) 2.87
Extensive variation in chromatin states across humans. Science (2013) 2.83
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Purgative bowel cleansing combined with simethicone improves capsule endoscopy imaging. Am J Gastroenterol (2007) 2.73
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A (2004) 2.54
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat Biotechnol (2011) 2.26
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (2007) 2.22
Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation (2004) 2.04
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology (2005) 2.03
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev (2008) 2.00
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem (2005) 1.99
Arabidopsis plasma membrane protein crucial for Ca2+ influx and touch sensing in roots. Proc Natl Acad Sci U S A (2007) 1.86
Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol (2006) 1.85
Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods (2008) 1.84
Two new complete genome sequences offer insight into host and tissue specificity of plant pathogenic Xanthomonas spp. J Bacteriol (2011) 1.80
Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem (2004) 1.76
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
A Measurable increase in oxidative damage due to reduction in superoxide detoxification fails to shorten the life span of long-lived mitochondrial mutants of Caenorhabditis elegans. Genetics (2007) 1.75
Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS One (2010) 1.75
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol (2005) 1.70
A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol (2008) 1.70
Outbreak of acute respiratory disease in China caused by B2 species of adenovirus type 11. J Clin Microbiol (2008) 1.67
Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors. Cell Res (2011) 1.67
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun (2004) 1.67
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des (2007) 1.66
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol (2004) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. Microbes Infect (2013) 1.59
Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis. Neurology (2014) 1.59
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem (2007) 1.58
Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res (2002) 1.57
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Laparoscopic treatment of endometrial cancer: systematic review. J Minim Invasive Gynecol (2013) 1.54
Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer (2010) 1.54
Androgenetic haploid embryonic stem cells produce live transgenic mice. Nature (2012) 1.51
Research and development of universal influenza vaccines. Microbes Infect (2010) 1.49
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs (2008) 1.48
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl (2002) 1.47
Long-term cardiovascular risk in women prescribed fertility therapy. J Am Coll Cardiol (2013) 1.46
Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ (2010) 1.44
Distance between external cortical bone and mandibular canal for harvesting ramus graft: a human cadaver study. J Periodontol (2010) 1.42
An adaptive altitude information fusion method for autonomous landing processes of small unmanned aerial rotorcraft. Sensors (Basel) (2012) 1.41
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides (2003) 1.41
Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem (2004) 1.40
Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr (2003) 1.40
Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice. Cardiology (2015) 1.38
Retracted Collecting duct carcinoma of the kidney: a clinicopathological study of five cases. Diagn Pathol (2013) 1.38
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine (2006) 1.36
Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis. J Cell Biol (2010) 1.36
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem (2007) 1.34
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res (2013) 1.33
Microbicides: stopping HIV at the gate. Lancet (2006) 1.31
Tissue-autonomous function of Drosophila seipin in preventing ectopic lipid droplet formation. PLoS Genet (2011) 1.30
Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid. J Biol Chem (2008) 1.30
Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice. Hepatology (2010) 1.29
Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A (2011) 1.28
A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect (2012) 1.28
Stem cell-delivery therapeutics for periodontal tissue regeneration. Biomaterials (2012) 1.27
Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs. PLoS One (2009) 1.27
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol (2006) 1.27